Energy Balance and Breast Cancer Aspects-II
- Conditions
- Stage II Breast CancerLCIS, Lobular Carcinoma in SituDCIS Grade 3Stage I Breast Cancer
- Interventions
- Other: Intervention. Exercise
- Registration Number
- NCT02240836
- Lead Sponsor
- Oslo University Hospital
- Brief Summary
The purpose of this study, the EBBA-II trial, is to determine whether a 12 month exercise program comprised of strength and endurance training among newly diagnosed breast cancer patients undergoing adjuvant therapy, will influence cardiopulmonary function. Secondary aims are to determine whether the 12 month exercise program will influence factors associated with metabolic profile, tumor growth, disease-free survival, overall mortality and breast cancer specific mortality. Furthermore, the effect on QoL parameters, and dietary factors will be assessed and evaluated.
- Detailed Description
The EBBA (Energy Balance and Breast cancer Aspects)-II study is a randomized clinical 12 month physical activity intervention trial, including female breast cancer patients diagnosed with histologically verified invasive cancer stage I-II or carcinoma in situ (DCIS/LCIS) grade 3.
* Participants are randomized to either control or intervention group 10 days +/- 2 days after surgery. The intervention start 3 weeks after surgery and continue throughout adjuvant treatments given (chemotherapy, radiation, endocrine therapy etc). The intervention group receive a detailed training program based on their own ventilatory maximal oxygen consumption (VO2max) at baseline. They meet for supervised training sessions in groups for 60 minutes x 2/ week during 12 months. In addition, they are informed to exercise at home for at least of total 120 minutes weekly aiming to perform a total of 240 minutes exercise, weekly. The patients in the control group receive standard of care without any restrictions regarding exercise.
* All participants will undergo a series of measurements before surgery, after surgery, 6 months and after the 12 months exercise intervention trial. Clinical measurements will include anthropometric measurements, fasting blood, fecal and urine samples and cardiopulmonary exercise test (CPET). Complete questionnaires (food diary (PFD)/food frequency questionnaires (FFQ), quality of life (QoL)).
* All participants will come to clinical examination and fasting blood sampling after 2, 3, 5 and 10 years follow up.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 545
- Age 18-75 years
- Newly diagnosed DCIS grade 3 or invasive breast cancer stage I, II, histologically verified.
- All ethnic groups, but participants have to speak and write the Norwegian language.
- Ability to join and maintain an intervention for 12 months
- Verified heart disease
- Dysregulated diabetes mellitus or thyroid disorders
- Muscular and skeletal or other disorders excluding regular physical activity performance
- Body Mass Index >40 kg/m2
- Previous surgical treatment for obesity
- Travel distance >1.5 hour from home to study site
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intervention. Exercise Intervention. Exercise The intervention starts 3-4 weeks after surgical treatment. The exercise program is performed in parallel with standard breast cancer treatment, and take place in supervised exercise groups by experienced physiotherapists. The duration of the intervention exercise program is 12 months, and the participants will attend the exercise groups for training 60 minutes twice a week. Additionally, they will exercise at home for at least 120 minutes a week, aiming to perform a total of 240 minutes of exercise per week
- Primary Outcome Measures
Name Time Method VO2max Baseline,12 months Change in VO2max from baseline to 12 months
- Secondary Outcome Measures
Name Time Method HbA1c Baseline,12 months Change in concentrations of HbA1c from baseline to 12 months
C-reactive Protein (CRP) Baseline,12 months Change in concentrations of CRP (mg/L) from baseline to 12 months
Total fat Baseline,12 months Change in total fat from baseline to 12 months
Energy from food diary Baseline,12 months Change in energy from food diary from baseline to 12 months
Heart rate Baseline,12 months Change in heart rate from baseline to 12 months
BMI Baseline,12 months Change in BMI from baseline to 12 months
Systolic blood pressure Baseline,12 months Change in systolic blood pressure from baseline to 12 months
Diastolic blood pressure Baseline,12 months Change in diastolic blood pressure from baseline to 12 months
Total cholesterol Baseline,12 months Change in total cholesterol from baseline to 12 months
LDL cholesterol Baseline,12 months Change in LDL cholesterol from baseline to 12 months
HDL cholesterol Baseline,12 months Change in HDL cholesterol from baseline to 12 months
Waist circumference Baseline,12 months Change in waist circumference from baseline to 12 months
Total cholesterol/HDL cholesterol Baseline,12 months Change in total cholesterol/HDL cholesterol from baseline to 12 months
Insulin Baseline,12 months Change in concentrations of blood insulin levels (µIU/mL) from baseline to 12 months
Triglycerides Baseline,12 months Change in concentrations of triglycerides from baseline to 12 months
Truncated fat Baseline,12 months Change in truncated fat from baseline to 12 months
Metabolic syndrome 12 months Dichotomous outcome (yes/no)
Trial Locations
- Locations (2)
St. Olavs Hospital
🇳🇴Trondheim, Norway
Oslo University Hospital
🇳🇴Oslo, Norway